Regulation and Signaling Pathways in Cancer Stem Cells: Implications for Targeted Therapy for Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2023 Oct 18

PMID 37853437

Authors

Zhen Zeng

Minyang Fu

Yuan Hu

Yuquan Wei

Xiawei Wei

Min Luo

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their behavior is regulated through a complex interplay of networks, including transcriptional, post-transcriptional, epigenetic, tumor microenvironment (TME), and epithelial-mesenchymal transition (EMT) factors. Numerous signaling pathways were found to be involved in the regulatory network of CSCs. The maintenance of CSC characteristics plays a pivotal role in driving CSC-associated tumor metastasis and conferring resistance to therapy. Consequently, CSCs have emerged as promising targets in cancer treatment. To date, researchers have developed several anticancer agents tailored to specifically target CSCs, with some of these treatment strategies currently undergoing preclinical or clinical trials. In this review, we outline the origin and biological characteristics of CSCs, explore the regulatory networks governing CSCs, discuss the signaling pathways implicated in these networks, and investigate the influential factors contributing to therapy resistance in CSCs. Finally, we offer insights into preclinical and clinical agents designed to eliminate CSCs.

Citing Articles

CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling.

Yan B, Lu Q, Gao T, Xiao K, Zong Q, Lv H Cell Death Dis. 2025; 16(1):150.

PMID: 40032820 PMC: 11876685. DOI: 10.1038/s41419-025-07470-x.

Selected Elements of the Tumor Microenvironment (MMP-2, MMP-7, TIMP-2, CXCL-9, CXCL-10) in the Serum of Pediatric Patients with Acute Lymphoblastic Leukemia.

Kaczorowska A, Miekus-Purwin N, Owczarzak A, Gabrych A, Wojciechowska M, Irga-Jaworska N Cells. 2025; 14(4).

PMID: 39996769 PMC: 11854448. DOI: 10.3390/cells14040297.

Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.

Zheng F, Zhang S, Chang A, Moon J, Wicha M, Wang S Int J Biol Sci. 2025; 21(4):1819-1836.

PMID: 39990669 PMC: 11844285. DOI: 10.7150/ijbs.101025.

Impact of G1 phase kinetics on the acquisition of stemness in cancer cells: the critical role of cyclin D.

Ahmadi Y, Faiq T, Abolhasani S Mol Biol Rep. 2025; 52(1):230.

PMID: 39951181 DOI: 10.1007/s11033-025-10351-3.

An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.

Jan A, Sofi S, Jan N, Mir M Future Oncol. 2025; 21(6):715-735.

PMID: 39936282 PMC: 11881842. DOI: 10.1080/14796694.2025.2461443.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S . CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012; 72(11):2768-79. PMC: 3367125. DOI: 10.1158/0008-5472.CAN-11-3567. View

Chai S, Ng K, Tong M, Lau E, Lee T, Chan K . Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 2016; 64(6):2062-2076. DOI: 10.1002/hep.28821. View

Boregowda R, Medina D, Markert E, Bryan M, Chen W, Chen S . The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget. 2016; 7(20):29689-707. PMC: 5045426. DOI: 10.18632/oncotarget.8822. View

Hou P, Ma X, Zhang Q, Wu C, Liao W, Li J . USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. Genes Dev. 2019; 33(19-20):1361-1366. PMC: 6771391. DOI: 10.1101/gad.326314.119. View

Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G . Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2018; 20(5):1836-1852. PMC: 7414524. DOI: 10.1093/bib/bby054. View

Le Grand M, Mukha A, Puschel J, Valli E, Kamili A, Vittorio O . Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation. Theranostics. 2020; 10(14):6411-6429. PMC: 7255021. DOI: 10.7150/thno.42602. View

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

Aoki N, Mochizuki K, Matsui Y . DNA methylation of the Fthl17 5'-upstream region regulates differential Fthl17 expression in lung cancer cells and germline stem cells. PLoS One. 2017; 12(2):e0172219. PMC: 5312872. DOI: 10.1371/journal.pone.0172219. View

10.

Liu M, Casimiro M, Wang C, Shirley L, Jiao X, Katiyar S . p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A. 2009; 106(45):19035-9. PMC: 2776463. DOI: 10.1073/pnas.0910009106. View

11.

Kim Y, Bagot M, Pinter-Brown L, Rook A, Porcu P, Horwitz S . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204. DOI: 10.1016/S1470-2045(18)30379-6. View

12.

Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L . Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology. 2011; 59(4):763-75. DOI: 10.1111/j.1365-2559.2011.03993.x. View

13.

Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

14.

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

15.

Liao Y, Jung S, Kim T . A-to-I RNA editing as a tuner of noncoding RNAs in cancer. Cancer Lett. 2020; 494:88-93. DOI: 10.1016/j.canlet.2020.08.004. View

16.

Darbelli L, Richard S . Emerging functions of the Quaking RNA-binding proteins and link to human diseases. Wiley Interdiscip Rev RNA. 2016; 7(3):399-412. DOI: 10.1002/wrna.1344. View

17.

Schott A, Landis M, Dontu G, Griffith K, Layman R, Krop I . Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013; 19(6):1512-24. PMC: 3602220. DOI: 10.1158/1078-0432.CCR-11-3326. View

18.

Su Y, Lai H, Chang Y, Chen G, Lee J . Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J. 2011; 30(15):3186-99. PMC: 3160185. DOI: 10.1038/emboj.2011.211. View

19.

Rodriguez-Pinilla S, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez M, Hernandez L . Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol. 2007; 20(4):474-81. DOI: 10.1038/modpathol.3800760. View

20.

Salpietro V, Dixon C, Guo H, Bello O, Vandrovcova J, Efthymiou S . AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019; 10(1):3094. PMC: 6626132. DOI: 10.1038/s41467-019-10910-w. View